Global Italy Peptide Receptor Radionuclide Therapy (PRRT) Market Restraints

Amol

posted on 3 years ago — updated on 1 second ago

240
views

Italy Peptide Receptor Radionuclide Therapy (PRRT) Market

There is just one licenced Italy Peptide Receptor Radionuclide Therapy (PRRT) market, and it is used to treat adult patients with foregut, midgut, and hindgut neuroendocrine tumours (GEP-NETs) that are somatostatin receptor positive. As a result, another significant factor limiting market expansion is the unavailability of various medications.

In addition, high treatment costs are anticipated to impede market expansion. For instance, the medicine Lutathera from Novartis Company costs US$ 99,900 for a complete course of treatment that includes four infusions.

https://knackersblogger.blogspot.com/2022/09/italy-peptide-receptor-radionuclide.html

Click here for Italy Peptide Receptor Radionuclide Therapy (PRRT) Market Press Release

Amol

Working in Coherent Market Insights. Coherent Market Insights is a global market intelligence and consulting organization, focused on assisting our plethora of clients achieve transformational growth by helping them make critical business decisions. We are headquartered in India, having office at global financial capital in the U.S. and sales consultants in United Kingdom and Japan.